MARKETS
Markets

GSK Says Health Canada Accepted Jemperli For Accelerated Review In Genetic Subtype Of Locally Advanced Rectal Cancer

Sep 24, 2026 · 08:07 AM ET· updated 1h ago

Share
Why It Matters

GSK's cancer medicine Jemperli got fast-track approval from Canada. This shows the drug helps a specific type of rectal cancer.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.